HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The growth inhibition of hepatocellular and cholangiocellular carcinoma cells by gemcitabine and the roles of extracellular signal-regulated and checkpoint kinases.

Abstract
We examined the effects of gemcitabine, a pyrimidine analogue, on hepatocellular carcinoma (HCC) and cholangiocellular carcinoma (CCC) cells. After HCC cells (HepG2, Hep3B, HLF and PLC/PRF/5) and CCC cells (HuCCT-1) were treated with gemcitabine, cellular growth, cell cycle, nuclear morphology and activity of signaling molecules were evaluated by WST-8 assays, flow cytometry analysis, Hoechst 33258 staining and Western blotting, respectively. We found that gemcitabine significantly inhibited the growth of HCC and CCC cells in a dose- and time-dependent manner. Gemcitabine induced cell cycle arrest at the G1 phase, however, the sub-G1 fraction was not observed and nuclear morphology did not indicate the induction of apoptosis. Gemcitabine induced differential activation of checkpoint kinases, Chk2 and Chk1, in HCC and CCC cells, respectively and gemcitabine activated extracellular signal-regulated kinase (ERK)1/2 in both cell types. After the cells were pretreated with a MEK inhibitor U0126, activations of these checkpoint kinases were abrogated and the cell death was enhanced. These results demonstrate that gemcitabine inhibited the growth of HCC and CCC cells by cell cycle arrest without apoptosis and that the ERK/Chk1/2 signaling pathway was in part responsible for the resistance to gemcitabine. Our findings shed light on treating patients with HCC and CCC by gemcitabine, especially when combined with a MEK inhibitor and Chk1/2 inhibitors.
AuthorsKazuya Matsumoto, Takakazu Nagahara, Jun-Ichi Okano, Yoshikazu Murawaki
JournalOncology reports (Oncol Rep) Vol. 20 Issue 4 Pg. 863-72 (Oct 2008) ISSN: 1021-335X [Print] Greece
PMID18813828 (Publication Type: Journal Article)
Chemical References
  • Antimetabolites, Antineoplastic
  • Deoxycytidine
  • Protein Kinases
  • Checkpoint Kinase 2
  • CHEK1 protein, human
  • CHEK2 protein, human
  • Checkpoint Kinase 1
  • Protein Serine-Threonine Kinases
  • Extracellular Signal-Regulated MAP Kinases
  • Gemcitabine
Topics
  • Antimetabolites, Antineoplastic (pharmacology)
  • Apoptosis (drug effects)
  • Bile Duct Neoplasms (drug therapy, pathology)
  • Bile Ducts, Intrahepatic
  • Carcinoma, Hepatocellular (drug therapy, pathology)
  • Cell Cycle (drug effects)
  • Cell Line, Tumor
  • Checkpoint Kinase 1
  • Checkpoint Kinase 2
  • Cholangiocarcinoma (drug therapy, pathology)
  • Deoxycytidine (analogs & derivatives, pharmacology)
  • Extracellular Signal-Regulated MAP Kinases (physiology)
  • Humans
  • Liver Neoplasms (drug therapy, pathology)
  • Protein Kinases (physiology)
  • Protein Serine-Threonine Kinases (physiology)
  • Gemcitabine

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: